Cole R P, Palushock S, Haboubi A
Allied Services Rehabilitation Hospital, Scranton, PA 18501-1103, USA.
Women Health. 1999;29(1):101-15. doi: 10.1300/J013v29n01_08.
Physicians use several pharmaceutical agents (e.g., hormone replacement therapy [HRT], calcitonin, bisphosphonates, calcium, and vitamin D) to manage osteoporosis. However, relatively little research has examined how physicians employ these agents in osteoporosis management. Additionally, researchers have not examined compliance with these treatments following the measurement of bone mass. Using a mail survey, we examined physicians' recommendation of, and women's compliance with, osteoporosis treatment modalities (stratified by fracture risk at the femoral neck and age) following bone mass measurement. We found that physicians recommended non-HRT treatment more often than HRT treatment to women with an increased risk of fracture, and women's acceptance of recommended treatments was relatively high following the measurement of bone mass.
医生使用多种药物制剂（如激素替代疗法[HRT]、降钙素、双膦酸盐、钙和维生素D）来治疗骨质疏松症。然而，相对较少的研究探讨了医生如何在骨质疏松症治疗中使用这些药物。此外，研究人员尚未研究在测量骨量后患者对这些治疗的依从性。我们通过邮件调查，研究了在测量骨量后，医生对骨质疏松症治疗方式（按股骨颈骨折风险和年龄分层）的推荐情况以及女性对这些治疗的依从性。我们发现，对于骨折风险增加的女性，医生推荐非HRT治疗的频率高于HRT治疗，并且在测量骨量后，女性对推荐治疗的接受度相对较高。
